ATE196092T1 - Wachstumshormon-enthaltendeproteinformulierung - Google Patents

Wachstumshormon-enthaltendeproteinformulierung

Info

Publication number: ATE196092T1
Authority: AT; Austria
Prior art keywords: growth hormone; pct; formulation; citrate; buffer substance
Prior art date: 1992-04-03

Application number

AT93908252T

Other languages

English (en)

Inventor

Staffan Castensson

Ebba Florin-Robertsson

Elvy Hoekby

Sirkka Thome

Original Assignee

Pharmacia & Upjohn Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-04-03

Filing date

1993-04-01

Publication date

2000-09-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20385860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE196092(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-04-01 Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab

2000-09-15 Application granted granted Critical

2000-09-15 Publication of ATE196092T1 publication Critical patent/ATE196092T1/de

Links

102000018997 Growth Hormone Human genes 0.000 title abstract 5
108010051696 Growth Hormone Proteins 0.000 title abstract 5
239000000122 growth hormone Substances 0.000 title abstract 5
238000009472 formulation Methods 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 abstract 3
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
239000012928 buffer substance Substances 0.000 abstract 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
235000004279 alanine Nutrition 0.000 abstract 1
235000001014 amino acid Nutrition 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
239000007864 aqueous solution Substances 0.000 abstract 1
235000019445 benzyl alcohol Nutrition 0.000 abstract 1
235000014633 carbohydrates Nutrition 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
239000000470 constituent Substances 0.000 abstract 1
239000013020 final formulation Substances 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
239000007972 injectable composition Substances 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
239000003755 preservative agent Substances 0.000 abstract 1
230000002335 preservative effect Effects 0.000 abstract 1
238000000746 purification Methods 0.000 abstract 1
150000005846 sugar alcohols Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

AT93908252T 1992-04-03 1993-04-01 Wachstumshormon-enthaltendeproteinformulierung ATE196092T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9201073A SE9201073D0 (sv)	1992-04-03	1992-04-03	Protein formulation
PCT/SE1993/000281 WO1993019776A1 (en)	1992-04-03	1993-04-01	Protein formulation comprising growth hormone

Publications (1)

Publication Number	Publication Date
ATE196092T1 true ATE196092T1 (de)	2000-09-15

Family

ID=20385860

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93908252T ATE196092T1 (de)	1992-04-03	1993-04-01	Wachstumshormon-enthaltendeproteinformulierung

Country Status (15)

Country	Link
US (1)	US5567677A (de)
EP (1)	EP0587858B2 (de)
JP (1)	JP3268557B2 (de)
AT (1)	ATE196092T1 (de)
AU (1)	AU666007B2 (de)
CA (1)	CA2102693C (de)
DE (1)	DE69329367T3 (de)
DK (1)	DK0587858T3 (de)
ES (1)	ES2150940T5 (de)
GR (1)	GR3034925T3 (de)
NO (1)	NO310804B1 (de)
NZ (1)	NZ251498A (de)
PT (1)	PT587858E (de)
SE (1)	SE9201073D0 (de)
WO (1)	WO1993019776A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5763394A (en) *	1988-04-15	1998-06-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5981485A (en) *	1997-07-14	1999-11-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5849704A (en) *	1991-12-20	1998-12-15	Novo Nordisk A/S	Pharmaceutical formulation
US6022858A (en) *	1991-12-20	2000-02-08	Novo Nordisk A/S	Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849700A (en) *	1991-12-20	1998-12-15	Novo Nordisk A/S	Pharmaceutical formulation
DK204791D0 (da) *	1991-12-20	1991-12-20	Novo Nordisk As	Hidtil ukendt farmaceutisk praeparat
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2719479B1 (fr) *	1994-05-04	1996-07-26	Sanofi Elf	Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5654278A (en) *	1994-10-13	1997-08-05	Novo Nordisk A/S	Composition and method comprising growth hormone and leucine
US5547696A (en) *	1994-10-13	1996-08-20	Novo Nordisk A/S	Pharmaceutical formulation
IL115592A (en) *	1994-10-13	2000-07-26	Novo Nordisk As	Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5631225A (en) *	1994-10-13	1997-05-20	Novo Nordisk A/S	Pharmaceutical formulation
US5705482A (en) *	1995-01-13	1998-01-06	Novo Nordisk A/S	Pharmaceutical formulation
US5552385A (en) *	1995-06-05	1996-09-03	Novo Nordisk A/S	Pharmaceutical formulation
DE19539574A1 (de)	1995-10-25	1997-04-30	Boehringer Mannheim Gmbh	Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
GB9526733D0 (en) *	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
AUPN801296A0 (en)	1996-02-12	1996-03-07	Csl Limited	Stabilised growth hormone formulation and method of preparation thereof
US20070179096A1 (en)	1996-04-24	2007-08-02	Novo Nordisk A/S	Pharmaceutical Formulation
ZA9711733B (en)	1996-12-31	1998-07-01	Monsanto Co	Method for solubilization and naturation of somatotropins
ZA9711731B (en) *	1996-12-31	1998-07-01	Monsanto Co	Aqueous glycerol formulations of somatotropin
JP3723857B2 (ja) *	1998-02-04	2005-12-07	日本ケミカルリサーチ株式会社	ヒト成長ホルモン含有水性医薬組成物
US6979442B1 (en)	1998-08-17	2005-12-27	Pfizer Inc.	Stabilized protein compositions
CN1360506A (zh) *	1999-07-12	2002-07-24	格兰迪斯生物技术有限公司	生长激素配方
RU2298415C2 (ru) *	2000-07-11	2007-05-10	Сандоз Аг	Композиции, включающие гормон роста
CA2418960A1 (en)	2000-08-07	2002-02-14	Inhale Therapeutic Systems, Inc.	Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
GB2371227A (en) *	2001-01-10	2002-07-24	Grandis Biotech Gmbh	Crystallisation - resistant aqueous growth hormone formulations
US7271150B2 (en) *	2001-05-14	2007-09-18	United States Of America, Represented By The Secretary, Department Of Health And Human Services	Modified growth hormone
WO2003059934A2 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2003072059A2 (en) *	2002-02-27	2003-09-04	Wake Forest University	Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
US20070065469A1 (en) *	2002-07-09	2007-03-22	Michael Betz	Liquid formulations with high concentration of human growth hormone (high) comprising glycine
EP1536835A1 (de) *	2002-07-09	2005-06-08	Sandoz AG	Phenolhaltige flüssige formulierungen mit hoher konzentration des humanen wachstumshormons (hgh)
JP4949828B2 (ja) *	2003-03-18	2012-06-13	アレストレーディングソシエテアノニム	溶液中での成長ホルモンの安定化
WO2005063298A1 (en)	2003-12-23	2005-07-14	Pharmacia Corporation	Stable growth hormone liquid formulation
BRPI0508798A (pt) *	2004-04-07	2007-09-04	Ares Trading Sa	formulação lìquida de hormÈnio de crescimento, composição farmacêutica, forma de apresentação da formulação lìquida de hormÈnio de crescimento e uso da formulação lìquida de hormÈnio de crescimento
GEP20105110B (en) *	2004-08-03	2010-11-10	Transtech Pharma Inc	Rage fusion proteins and their use
SG161242A1 (en) *	2004-08-03	2010-05-27	Transtech Pharma Inc	Rage fusion proteins and methods of use
KR101149454B1 (ko) *	2004-08-24	2012-05-25	간가와 겐지	생리활성 펩티드의 액상 제제
DE602005009856D1 (de) *	2004-11-09	2008-10-30	Ares Trading Sa	Verfahren zur reinigung von fsh
US20070015689A1 (en) *	2005-06-23	2007-01-18	Alza Corporation	Complexation of metal ions with polypeptides
WO2007022799A1 (en) *	2005-08-26	2007-03-01	Ares Trading S.A.	Process for the preparation of glycosylated interferon beta
WO2007056105A2 (en) *	2005-11-02	2007-05-18	Transpharma Medical Ltd.	Human growth hormone patch formulations
EP1960419B1 (de) *	2005-12-09	2016-03-16	Ares Trading S.A.	Verfahren zur aufreinigung von fsh oder einer fsh-mutante
JP5314428B2 (ja) *	2005-12-23	2013-10-16	ジーコデールシステムズアクチボラゲット	測位用パターン
EP1989227A2 (de) *	2006-02-09	2008-11-12	Transtech Pharma, Inc.	Rage-fusionsproteine und anwendungsverfahren
SG171670A1 (en) *	2006-05-05	2011-06-29	Transtech Pharma Inc	Rage fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (en) *	2007-02-15	2008-08-21	Transtech Pharma, Inc.	Rage - immunoglobulin fusion proteins
EP2162540A2 (de)	2007-05-22	2010-03-17	Amgen Inc.	Zusammensetzungen und verfahren zur herstellung biologisch aktiver fusionsproteine
WO2009053360A1 (en) *	2007-10-22	2009-04-30	Merck Serono S.A.	Method for purifying an fc-containing protein
US20100249381A1 (en) *	2007-10-22	2010-09-30	David Delvaille	Method for Purifying FC-Fusion Proteins
AU2010240569A1 (en)	2009-04-20	2011-10-20	Pfizer Inc.	Control of protein glycosylation and compositions and methods relating thereto
EP2427215A1 (de) *	2009-05-07	2012-03-14	Novo Nordisk Health Care AG	Stabile pharmazeutische zusammensetzungen von mit einem oxim-linker derivatisiertem peptid
EP2501367B1 (de) *	2009-11-17	2015-01-21	Ipsen Pharma S.A.S.	Formulierung für HGH- und RHIGF-1-Kombination
KR101337797B1 (ko)	2010-07-14	2013-12-06	한미사이언스 주식회사	지속형 인간 성장 호르몬 결합체 액상 제제
US10064951B2 (en) *	2012-03-30	2018-09-04	Hanmi Science Co., Ltd.	Liquid formulation of highly concentrated long-acting human growth hormone conjugate
EP3689335A1 (de) *	2013-09-27	2020-08-05	Hanmi Pharm. Co., Ltd.	Menschliches hormonwachstumspräparat mit verzögerter freisetzung
EP3079668A1 (de)	2013-12-09	2016-10-19	Durect Corporation	Pharmazeutisch aktive wirkstoffkomplexe, polymerkomplexe und zusammensetzungen und verfahren damit
US20160015789A1 (en) *	2014-07-17	2016-01-21	Teva Pharmaceutical Industries, Ltd.	FORMULATIONS OF AN ALBUMIN hGH FUSION PROTEIN
US11738068B2 (en) *	2018-06-25	2023-08-29	Jcr Pharmaceuticals Co., Ltd.	Protein-containing aqueous liquid formulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4783441A (en) *	1979-04-30	1988-11-08	Hoechst Aktiengesellschaft	Aqueous protein solutions stable to denaturation
US4774091A (en) *	1983-10-14	1988-09-27	Sumitomo Pharmaceuticals Company, Ltd.	Long-term sustained-release preparation
EP0189673B1 (de) *	1984-12-24	1990-09-26	Sumitomo Pharmaceuticals Company, Limited	Stabiles GRF-Präparat
PT83095B (en) *	1985-07-30	1987-12-23	Int Minerals & Chem Corp	Method for the stabilization of growth promoting hormones using polyoxyethylene-polyoxypropylene copolymers
US4816568A (en) *	1986-05-16	1989-03-28	International Minerals & Chemical Corp.	Stabilization of growth hormones
US4917685A (en) *	1986-05-16	1990-04-17	International Minerals & Chem. Corp.	Delivery device for the administration of stabilized growth promoting hormones
EP0303746B2 (de) *	1987-08-21	1998-12-02	Mallinckrodt Group Inc.	Stabilisierung von Wachstumshormonen
US4837202A (en) †	1987-09-14	1989-06-06	Pitman-Moore, Inc.	Method for stimulating the immune system
US5096885A (en) *	1988-04-15	1992-03-17	Genentech, Inc.	Human growth hormone formulation
JPH01308235A (ja) *	1988-06-03	1989-12-12	Yamanouchi Pharmaceut Co Ltd	ヒト成長ホルモン経鼻剤
US5008244A (en) *	1989-05-15	1991-04-16	Pitman-Moore, Inc.	Method for increasing fertility in animals
CA2020654A1 (en) *	1989-07-07	1991-01-08	Yohko Akiyama	Stabilized fgf composition and production thereof
IN172427B (de) *	1989-11-14	1993-07-24	Fidia Spa
US5217954A (en) *	1990-04-04	1993-06-08	Scios Nova Inc.	Formulations for stabilizing fibroblast growth factor
US5126324A (en)	1990-06-07	1992-06-30	Genentech, Inc.	Method of enhancing growth in patients using combination therapy
AU1757092A (en) *	1991-03-28	1992-11-02	Genentech Inc.	Stable growth hormone metal ion formulations
DK204791D0 (da) *	1991-12-20	1991-12-20	Novo Nordisk As	Hidtil ukendt farmaceutisk praeparat
EP0639202B1 (de) †	1992-04-30	1998-11-25	Cor Therapeutics, Inc.	Stabile zusammensetzung von polypeptiden
DK0955062T3 (da) *	1992-07-31	2007-09-17	Genentech Inc	Vandig formulering indeholdende humant væksthormon

1992
- 1992-04-03 SE SE9201073A patent/SE9201073D0/xx unknown
1993
- 1993-04-01 WO PCT/SE1993/000281 patent/WO1993019776A1/en not_active Ceased
- 1993-04-01 ES ES93908252T patent/ES2150940T5/es not_active Expired - Lifetime
- 1993-04-01 DE DE69329367T patent/DE69329367T3/de not_active Expired - Fee Related
- 1993-04-01 AU AU39135/93A patent/AU666007B2/en not_active Ceased
- 1993-04-01 JP JP51737893A patent/JP3268557B2/ja not_active Expired - Lifetime
- 1993-04-01 DK DK93908252T patent/DK0587858T3/da active
- 1993-04-01 PT PT93908252T patent/PT587858E/pt unknown
- 1993-04-01 US US08/162,017 patent/US5567677A/en not_active Expired - Lifetime
- 1993-04-01 CA CA002102693A patent/CA2102693C/en not_active Expired - Lifetime
- 1993-04-01 AT AT93908252T patent/ATE196092T1/de not_active IP Right Cessation
- 1993-04-01 NZ NZ251498A patent/NZ251498A/en not_active IP Right Cessation
- 1993-04-01 EP EP93908252A patent/EP0587858B2/de not_active Expired - Lifetime
- 1993-11-30 NO NO19934355A patent/NO310804B1/no unknown
2000
- 2000-11-28 GR GR20000402632T patent/GR3034925T3/el unknown

Also Published As

Publication number	Publication date
ES2150940T5 (es)	2008-04-16
US5567677A (en)	1996-10-22
EP0587858B1 (de)	2000-09-06
DE69329367T3 (de)	2008-06-19
DE69329367D1 (de)	2000-10-12
AU666007B2 (en)	1996-01-25
CA2102693C (en)	2008-06-17
PT587858E (pt)	2001-02-28
EP0587858A1 (de)	1994-03-23
SE9201073D0 (sv)	1992-04-03
EP0587858B2 (de)	2007-11-14
GR3034925T3 (en)	2001-02-28
NZ251498A (en)	1995-07-26
DK0587858T3 (da)	2000-12-18
NO934355L (no)	1993-12-01
AU3913593A (en)	1993-11-08
JP3268557B2 (ja)	2002-03-25
NO310804B1 (no)	2001-09-03
CA2102693A1 (en)	1993-10-04
DE69329367T2 (de)	2001-06-21
WO1993019776A1 (en)	1993-10-14
ES2150940T3 (es)	2000-12-16
NO934355D0 (no)	1993-11-30
JPH06508156A (ja)	1994-09-14

Legal Events

Date	Code	Title
2000-12-15	UEP	Publication of translation of european patent specification
2008-04-15	EEFA	Change of the company name
2008-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE196092T1 (de)	2000-09-15	Wachstumshormon-enthaltendeproteinformulierung
EP0747092A3 (de)	1998-04-08	Lösungsflüssigkeit für durch Iontophorese zugeführte Medikamente
CA2275890A1 (en)	1998-07-02	Stable liquid interferon formulations
DK1017413T3 (da)	2003-02-03	Flydende formulering af interferon-beta
ATE175424T1 (de)	1999-01-15	Verfahren zur gewinnung von hochreinem von willebrand-faktor
PL274485A1 (en)	1989-04-17	Method of obtaining stable preparations of human proteins
DE3585556D1 (de)	1992-04-16	Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten.
DK0910399T3 (da)	2003-01-06	Stabilt farmaceutisk BDNF-præparat
DK1044015T3 (da)	2008-12-08	Formuleringer med amylinagonistpeptider og insulin
EE9900428A (et)	2000-04-17	Köhavastased ravimkoostised
ATE228005T1 (de)	2002-12-15	Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form
Li	1952	Recent studies on the problems involved in the preparation, properties and bioassay of adrenocorticotrophic hormone
Holbrook et al.	1975	The identification of a peptide in human parotid saliva particularly active in enhancing the glycolytic activity of the salivary micro-organisms
DK0641216T3 (da)	1998-01-26	Farmaceutisk præparat indeholdende IL-6
KR860006982A (ko)	1986-10-06	안정한 감마 인터페론 제형의 제조방법
Donohue Jr et al.	1981	Glucose-6-phosphate dehydrogenase Partial characterization of the rat liver and uterine enzymes
Leaver	1969	Studies on certain peptide fractions isolated from human dentine
BR9006746A (pt)	1991-08-06	Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
Lafeber	1988	Comparison of PTH and hypocalcin in mammalian and teleost bioassays
KR920700666A (ko)	1992-08-10	소형 펩티드의 안정화 액상제제